Related Experiment Video

Updated: Jun 20, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently

Julien Viaud1, Jeffrey R Peterson

  • 1Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Molecular Cancer Therapeutics
|September 3, 2009
PubMed

Insights

IPA-3 is a novel allosteric inhibitor targeting Pak kinase activation. This covalent inhibitor specifically binds the Pak1 regulatory domain, offering a new strategy for selective kinase inhibition in cancer therapy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Kinases are crucial therapeutic targets in oncology, but ATP-competitive inhibitors often cause toxicity due to off-target effects.
  • Allosteric inhibitors offer improved selectivity but are less common.

Purpose of the Study:

  • To elucidate the mechanism of action of IPA-3, an allosteric inhibitor of Pak kinase.
  • To explore the potential of IPA-3 as a selective kinase inhibitor.

Main Methods:

  • Investigated IPA-3's binding to the Pak1 regulatory domain using biochemical assays.
  • Utilized radiolabeled IPA-3 to assess inhibitor specificity and reversibility.
  • Conducted cell experiments to determine Pak1's role in cellular processes.

Main Results:

  • IPA-3 binds covalently to the Pak1 regulatory domain, blocking Cdc42 binding.
  • Inhibition is conformationally specific, with preactivated Pak1 unaffected by IPA-3.
  • IPA-3 binding is specific and reversible in reducing environments.
  • Pak1 activation is implicated in phorbol-ester-stimulated membrane ruffling.

Conclusions:

  • IPA-3 represents a novel allosteric inhibitor targeting Pak kinase activation through covalent modification of its regulatory domain.
  • This mechanism offers a unique approach for achieving high kinase selectivity, potentially reducing off-target toxicities.
  • The findings highlight the therapeutic potential of conformationally specific, allosteric kinase inhibitors in cancer treatment.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...